이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Guangzhou Baiyunshan Pharmaceutical Holdings 미래 성장
Future 기준 확인 1/6
Guangzhou Baiyunshan Pharmaceutical Holdings (는) 각각 연간 4.5% 및 6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 1.1% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 10.6% 로 예상됩니다.
주요 정보
4.5%
수익 성장률
-1.1%
EPS 성장률
| Healthcare 수익 성장 | 16.7% |
| 매출 성장률 | 6.0% |
| 향후 자기자본 수익률 | 10.6% |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 12 Jun 2024 |
최근 미래 성장 업데이트
업데이트 없음
Recent updates
Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
Jun 26
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227
Jun 03The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon
May 23Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
May 13Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?
Mar 08Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price
Feb 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward
Feb 10Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Jan 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Popularity With Investors Is Under Threat From Overpricing
Jan 09With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Nov 28A Look At The Intrinsic Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 15We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Oct 19Returns On Capital At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have Hit The Brakes
Oct 03Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Worth HK$21.9 Based On Its Intrinsic Value?
Aug 15Should You Be Adding Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) To Your Watchlist Today?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns Have Hit A Wall
Jul 02Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jun 01Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Caught The Eye Of Investors
May 01The Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Aren't Growing
Mar 28Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Feb 23With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Jan 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Some Way To Go To Become A Multi-Bagger
Dec 24Estimating The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 24Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Using Too Much Debt?
Nov 11Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year
May 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 83% Above Its Share Price
Apr 29Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Apr 10We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Jan 09Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Rock Solid Balance Sheet
Oct 11Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jul 12Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All
May 26How Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stand Up To These Simple Dividend Safety Checks?
Apr 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Could Be 21% Above Their Intrinsic Value Estimate
Apr 08These 4 Measures Indicate That Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Using Debt Reasonably Well
Mar 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Mar 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Shareholders Have Enjoyed A 24% Share Price Gain
Feb 11
Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) A Smart Pick For Income Investors?
Jan 26Could The Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Ownership Structure Tell Us Something Useful?
Jan 06Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet
Dec 23Here's Why We Don't Think Guangzhou Baiyunshan Pharmaceutical Holdings's (HKG:874) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 09Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Nov 26수익 및 매출 성장 예측
| 날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2026 | 90,280 | 4,590 | N/A | 3,638 | 3 |
| 12/31/2025 | 85,879 | 4,489 | N/A | 4,546 | 5 |
| 12/31/2024 | 80,458 | 4,192 | N/A | 5,229 | 4 |
| 3/31/2024 | 76,833 | 4,105 | 2,092 | 3,804 | N/A |
| 12/31/2023 | 75,515 | 4,056 | 2,475 | 4,104 | N/A |
| 9/30/2023 | 74,167 | 4,283 | 2,958 | 4,601 | N/A |
| 6/30/2023 | 73,538 | 4,188 | 2,954 | 4,546 | N/A |
| 3/31/2023 | 71,878 | 4,069 | 1,898 | 3,242 | N/A |
| 12/31/2022 | 70,788 | 3,967 | 5,615 | 6,999 | N/A |
| 9/30/2022 | 70,280 | 3,883 | 1,805 | 3,187 | N/A |
| 6/30/2022 | 70,106 | 3,807 | 3,878 | 5,201 | N/A |
| 3/31/2022 | 69,507 | 3,898 | 3,606 | 4,910 | N/A |
| 12/31/2021 | 69,014 | 3,720 | 4,419 | 5,673 | N/A |
| 9/30/2021 | 68,329 | 3,568 | 4,862 | 5,982 | N/A |
| 6/30/2021 | 67,333 | 3,653 | 4,133 | 5,174 | N/A |
| 3/31/2021 | 64,735 | 3,359 | 4,726 | 5,674 | N/A |
| 12/31/2020 | 61,674 | 2,915 | -291 | 585 | N/A |
| 9/30/2020 | 61,774 | 2,688 | 3,526 | 4,389 | N/A |
| 6/30/2020 | 62,081 | 2,406 | 2,641 | 3,543 | N/A |
| 3/31/2020 | 63,881 | 2,966 | 2,041 | 4,414 | N/A |
| 12/31/2019 | 64,952 | 3,189 | 2,623 | 5,022 | N/A |
| 9/30/2019 | 62,420 | 3,161 | 563 | 2,884 | N/A |
| 6/30/2019 | 60,735 | 3,370 | 911 | 3,088 | N/A |
| 3/31/2019 | 53,380 | 3,943 | 1,003 | 1,616 | N/A |
| 12/31/2018 | 42,234 | 3,441 | 4,738 | 5,217 | N/A |
| 9/30/2018 | 34,863 | 4,015 | 3,077 | 3,378 | N/A |
| 6/30/2018 | 24,679 | 3,523 | 1,918 | 2,171 | N/A |
| 3/31/2018 | 22,575 | 2,482 | 2,065 | 2,280 | N/A |
| 1/1/2018 | 20,954 | 2,062 | N/A | 1,834 | N/A |
| 9/30/2017 | 20,459 | 1,937 | N/A | 1,888 | N/A |
| 6/30/2017 | 20,294 | 1,834 | N/A | 1,649 | N/A |
| 3/31/2017 | 20,273 | 1,583 | N/A | 2,157 | N/A |
| 12/31/2016 | 20,036 | 1,508 | N/A | 2,545 | N/A |
| 9/30/2016 | 19,598 | 1,397 | N/A | 2,806 | N/A |
| 6/30/2016 | 19,502 | 1,357 | N/A | 2,427 | N/A |
| 3/31/2016 | 19,442 | 1,345 | N/A | 2,442 | N/A |
| 12/31/2015 | 19,125 | 1,300 | N/A | 1,942 | N/A |
| 9/30/2015 | 19,244 | 1,300 | N/A | 1,499 | N/A |
| 6/30/2015 | 19,270 | 1,295 | N/A | 1,859 | N/A |
| 3/31/2015 | 18,876 | 1,241 | N/A | 1,827 | N/A |
| 12/31/2014 | 18,818 | 1,194 | N/A | 1,749 | N/A |
| 9/30/2014 | 19,049 | 1,106 | N/A | 1,902 | N/A |
| 6/30/2014 | 18,563 | 1,067 | N/A | 1,136 | N/A |
| 3/31/2014 | 18,130 | 1,036 | N/A | 895 | N/A |
| 12/31/2013 | 17,608 | 980 | N/A | 1,336 | N/A |
| 9/30/2013 | 16,744 | 891 | N/A | 1,253 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: 874 의 연간 예상 수익 증가율( 4.5% )이 saving rate( 2.2% 보다 높습니다. ).
수익 vs 시장: 874 의 연간 수익( 4.5% ) Hong Kong 시장( 11.7% 보다 느리게 성장할 것으로 예상됩니다. 11.7% 연간).
고성장 수익: 874 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.
수익 대 시장: 874 의 수익(연간 6% ) Hong Kong 시장( 7.8% 보다 느리게 성장할 것으로 예상됩니다. 7.8% 연간).
고성장 수익: 874 의 수익(연간 6% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: 874 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 10.6 %).